ZA978557B - Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease. - Google Patents
Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.Info
- Publication number
- ZA978557B ZA978557B ZA9708557A ZA978557A ZA978557B ZA 978557 B ZA978557 B ZA 978557B ZA 9708557 A ZA9708557 A ZA 9708557A ZA 978557 A ZA978557 A ZA 978557A ZA 978557 B ZA978557 B ZA 978557B
- Authority
- ZA
- South Africa
- Prior art keywords
- alzheimer
- disease
- agents
- determination
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19641180A DE19641180A1 (en) | 1996-09-24 | 1996-09-24 | A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA978557B true ZA978557B (en) | 1998-03-26 |
Family
ID=7807996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9708557A ZA978557B (en) | 1996-09-24 | 1997-09-23 | Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease. |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU4775797A (en) |
DE (1) | DE19641180A1 (en) |
WO (1) | WO1998013488A2 (en) |
ZA (1) | ZA978557B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679534B2 (en) | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
SG113454A1 (en) | 1998-09-24 | 2005-08-29 | Upjohn Co | Alzheimer's disease secretase |
US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6844148B1 (en) | 1998-09-24 | 2005-01-18 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6313268B1 (en) | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US7115410B1 (en) | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
CA2359785A1 (en) | 1999-02-10 | 2000-08-17 | John P. Anderson | .beta.-secretase enzyme compositions and methods |
DE19920514A1 (en) * | 1999-05-05 | 2000-11-16 | Boehringer Ingelheim Pharma | Methods for finding proteases that specifically cleave membrane-bound substrates |
US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
DE19941039A1 (en) * | 1999-08-28 | 2001-03-01 | Boehringer Ingelheim Pharma | gamma-secretase in vitro test system |
US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
WO2001058476A2 (en) * | 2000-02-11 | 2001-08-16 | The European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
CA2401155A1 (en) * | 2000-04-05 | 2001-10-11 | Alcide Barberis | Method for identify polypeptides with protease activity |
CA2313828A1 (en) * | 2000-08-01 | 2002-02-01 | Institut De Recherches Cliniques De Montreal/Ircm | Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production |
CA2437480A1 (en) * | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid .beta. precursor disorder |
AU2002359301B2 (en) | 2001-10-23 | 2008-07-03 | Comentis, Inc. | Beta-secretase inhibitors and methods of use |
US7045311B2 (en) | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
CH698246B1 (en) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test to identify inhibitors of beta secretases. |
WO2003087842A1 (en) * | 2002-04-18 | 2003-10-23 | Esbatech Ag | Method for the identification of modulators of a secretase activity |
JP2004000060A (en) * | 2002-05-31 | 2004-01-08 | Otsuka Pharmaceut Co Ltd | METHOD FOR SCREENING COMPOUND AFFECTING PRODUCTION OF AMYLOID beta |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0327960A1 (en) * | 1988-02-11 | 1989-08-16 | F. Hoffmann-La Roche Ag | Secretable forms of alkaline phosphatase |
US5851787A (en) * | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
TW327194B (en) * | 1992-05-01 | 1998-02-21 | American Cyanamid Co | Novel amyloid precursor proteins and methods of using same |
AU679675B2 (en) * | 1992-05-11 | 1997-07-10 | Bayer Corporation | Methods for detecting beta amyloid precursor protein processing enzymes |
ZA936492B (en) * | 1992-09-10 | 1995-03-02 | Lilly Co Eli | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. |
DE69334337D1 (en) * | 1992-10-26 | 2010-08-26 | Elan Pharm Inc | Method for identifying inhibitor compounds of the release of beta-amyloid peptide (BAP) |
GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
AU6383396A (en) * | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
-
1996
- 1996-09-24 DE DE19641180A patent/DE19641180A1/en not_active Withdrawn
-
1997
- 1997-09-22 AU AU47757/97A patent/AU4775797A/en not_active Abandoned
- 1997-09-22 WO PCT/EP1997/005149 patent/WO1998013488A2/en active Application Filing
- 1997-09-23 ZA ZA9708557A patent/ZA978557B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE19641180A1 (en) | 1998-03-26 |
WO1998013488A2 (en) | 1998-04-02 |
WO1998013488A3 (en) | 1998-09-11 |
AU4775797A (en) | 1998-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA978557B (en) | Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease. | |
EP1007048A4 (en) | Identification of agents for use in the treatment of alzheimer's disease | |
EP1043991A4 (en) | Treatment for alzheimer's disease | |
GB2367060B (en) | Alzheimer's disease secretase,app substrates therefor,and uses therefor | |
EP0963219A4 (en) | Manipulations of nitrosative and oxidatives stress in the treatment of disease | |
PL348226A1 (en) | Compounds for the antemortem diagnosis of alzheimer's disease and in vivo | |
HUP0003852A3 (en) | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
AU5716898A (en) | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease | |
IL105216A0 (en) | Method and kit for the diagnosis of alzheimer's disease | |
AP2001002102A0 (en) | Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas | |
AU3279395A (en) | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes | |
EP0685219A3 (en) | Hair treatment agent and process for its use. | |
EP0691112A3 (en) | Ophthalmic treatment apparatus and its use | |
EP1011644A4 (en) | Methods and apparatus for treatment of parkinson's disease | |
IL127146A0 (en) | Transdermal propentofylline compositions for the treatment of alzheimer's disease | |
ZA989365B (en) | Preparation for treating alzheimer's disease | |
ZA964761B (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders. | |
AU3745895A (en) | Use of gaba antagonists in the treatment of emesis | |
PH31643A (en) | 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease. | |
AU1405899A (en) | Treatment for alzheimer's disease | |
AU2002301084A1 (en) | Identification of agents for use in the treatment of alzheimer's disease | |
ZA947262B (en) | Use of transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine and its use for the treatment of alzheimer's disease | |
ZA9610264B (en) | Preparation for use in the treatment of skin disorders. | |
GB2357767B (en) | Alzheimer's disease secretase app substrates therefor and uses therefor | |
GB9709416D0 (en) | Methods for treatment of alzheimer's disease using azaspiranes |